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Abstract
Background: In many countries relatives are asked to consent on behalf of ICU patients prior to inclusion in clinical 
trials. However, the attitudes to drug trials among relatives of unconscious ICU patients are largely unknown.
Methods: We performed a prospective questionnaire survey at two university hospital ICUs of the next-of-kin to 50 
unconscious adult patients. They were asked to complete a questionnaire within 48 hours of the patients' acute ICU 
admission.
Results: Forty-two relatives returned the questionnaire of which 41 were completed by direct family members and in 
one case by a friend to the patient.
The majority of relatives (36/42) were positive/positive with some scepticism towards performing drug trials in 
unconscious ICU patients and 30/42 would most likely accept trial-participation by their relative. The majority (30/42) 
agreed that they should decide if their relative was to participate in a drug trial and 24 of these found that the treating 
clinician/ICU consultant should also consent. The majority (27/42) found that deferred consent would be acceptable if 
there was a limited time frame for initiation of treatment, however 8 respondents found this unacceptable when the 
intervention was a new drug.
The majority of relatives stipulated that adherence to legislation, treatment benefit for the study patient and for future 
patients, no patient-risk or -discomfort and development of new drugs were important factors if their relative was to 
participate in an ICU drug trial. When questioned about doctors' motives for performing drug trials the wish for drug 
development and better patient care were highly rated among relatives.
Conclusions: In general, relatives to unconscious ICU patients expressed positive attitudes to drug trials in the ICU and 
the inclusion of their relative in drug trials. Consent by next-of-kin and deferred consent was acceptable to the majority 
of relatives.
Background
Researchers including critically ill patients into clinical
trials are challenged by the ethical dilemma that many of
these patients cannot give informed consent. In one study
in the intensive care setting less than 3% of the included
patients were able to consent prior to randomisation [1].
Therefore other procedures for consent are required
when performing trials in this setting. In many countries
patient relatives act as the legal representative to consent
on behalf of the patient [2]. Consent rates by relatives
when ICU patients are included into large interventional
trials vary from 58 to 96% [3,4] and little is known of the
attitudes to consent and perceived risk/benefit among
relatives of critically ill patients. To investigate this, we
performed a questionnaire survey among relatives of
unconscious adult patients, who had been acutely admit-
ted to the ICU.
Methods
During two 4-week study periods, 50 relatives to acutely
admitted adult ICU patients with impaired consciousness
were asked to fill in a questionnaire within the first 48
hours of admission to the general ICUs at Rigshospitalet
or Herlev Hospital in Copenhagen, Denmark. These hos-
pitals receive patients from the whole of Denmark and
suburban Copenhagen, respectively. The relative had to
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Page 2 of 5be the legal representative of the patient (i.e. nearest rela-
tive: spouse, parent, child or if the patient had no family, a
friend) and were included by an ICU consultant (AP or
JB), a research fellow (MI) or a research nurse, who gave
information about the survey and the questionnaire to
the relative. The relatives were encouraged to fill in the
survey immediately and return the questionnaire to a
member of the trial team or the patients contact nurse.
There was no follow up of non-responders. Relatives who
were unable to understand and read Danish or who had
been asked for patient-inclusion into a research study
were not invited to participate.
The questionnaire was modified from a pre-existing
questionnaire study of cancer patients and was adapted to
be relevant to relatives to ICU patients [5]. Following the
modifications to the questionnaire, it was preliminary tri-
alled on five relatives to ICU patients, who were inter-
viewed about its comprehensibility and user friendliness.
This resulted in further adjustments and the final ques-
tions can be read in Results, Tables, Fig. 1 and Additional
file 1 (translated from Danish).
We registered the sex, relation of the relative as well as
patient age, diagnosis, reason for unconsciousness and
sequential organ failure assessment (SOFA) score [6] at
the time of questionnaire hand out. The survey fulfilled
demands of Danish law, in which questionnaire-surveys
are exempted from review by the ethical committee sys-
tem.
Data were given as numbers of participants or medians
with ranges where appropriate. No statistical analyses
were performed and the sample size was chosen prag-
matically.
Results
Forty-two of the 50 relatives returned the questionnaire
giving a response rate of 84%. Of these, 23 were spouses,
8 parents, 8 children, 2 were siblings and 1 was a friend of
the ICU patient. The majority of relatives were females
(27/42). The patients' diagnosis included severe sepsis
(29), trauma (8), other acute surgical conditions (4) and
hepatic failure (1) and all required mechanical ventila-
tion. The median age of the patients was 55 (range 18 -
82) years and SOFA score at inclusion 9 (1 - 18). The rea-
son for impaired conscious level was mainly sedation in
35 patients and encephalopathy in 7 patients.
Relatives' knowledge about the purpose of drug trials
In response to the question 'What do you think is the pur-
pose of performing drug trials?' the majority of respon-
dents marked the answers 'to improve care of future
patients' (38/42) and 'to increase doctors knowledge in
general' (31/42), whereas 25/42 responded'to improve
care of the patient in the trial'. Three respondents marked
'To reduce the total cost of treatment' and four marked
'So that drug companies can earn more money'.
Relatives' attitudes to drug trials and consent
The majority of relatives were positive with some scepti-
cism (36/42) to drug trials in unconscious ICU patients
and would most likely accept (30/42) the participation of
their relative in a trial. A minority (3/42) felt that drug tri-
als should not be performed in unconscious patients
(Table 1 &2).
The majority(32/42) stated that they should decide if
their relative was to participate in an ICU drug trial and
24 of these found that the treating clinician/ICU consul-
tant should also give consent (Fig. 1). Very few wished
that the researcher (1/42), general practitioner (4/42) or
coroner (1/42) were to decide if their relative was to par-
ticipate in a trial (Fig. 1).
Adherence to legislation, gain for the patient, gain for
future patients, development of new drugs and no risk or
discomfort for the patient were very important or impor-
tant for the majority of respondents if their relative were
to participate in a drug trial in the ICU (Table 3).
Twenty-nine of the 42 respondents felt it acceptable to
commence a drug trial before consent was obtained if the
time window for initiation of treatment was narrow and
therefore precluded obtaining consent. However 8 of the
29 would not endorse this if the trial was of a new drug
Figure 1 Who are to decide if an unconscious patient is to partic-
ipate in a drug trial? Forty-two relatives of unconscious ICU patients 
were asked the above question. More than one answer could be 
marked. No relatives marked 'Do not know'. In A. all answer are dis-
played. In B. the answers of those relatives marking two answers (n = 
27) are displayed.
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answered 'no' to this question on deferred consent and
another 10 answered 'do not know'.
Attitudes to doctors' motives for performing drug trials
Asked about doctors' motives for performing drug trials
altruistic motives ('find new therapies', 'gain new knowl-
edge' and 'help patients') were highly rated by the respon-
dents (Table 3), whereas the majority thought that
financial matters ('reduce costs of treatments' and 'earn
money') and 'wish to make carrier' were of minor or no
importance (Table 3).
Discussion
The principle findings of this study were that the majority
of relatives to unconscious ICU patients were positive or
positive with some scepticism towards performing drug
trials in unconscious ICU patients and towards the doc-
tors/researchers performing such trials.
The majority would most likely accept participation in
a drug trial by their relative, though on the premise that
they should give consent if their relative was to partici-
pate. This is in line with results from a Swiss question-
naire survey where survivors of intensive care and their
relatives wanted consent by the relative if the uncon-
scious patient was to participate in a trial [7]. This notion
is also supported by observations in a study of parents in
a paediatric ICU, among whom the vast majority wanted
to consent for their child's participation in a trial [8]. We
know that relatives have difficulties when they are to
express adult ICU patients' wishes for trial participation
at least for hypothetical trials [9]. Furthermore up to 50%
of relatives to ICU patients are hesitant in sharing the
decision-making process for therapeutic interventions
[10]. However, there appears to agreement between ICU
patients and relatives on consent procedures in general as
indicated by the aforementioned Swiss study [7].
In addition to adherence to legislation and no patient-
risk or -discomfort, relatives had altruistic motives for
patient participation in a drug trial. The relatives
expected gain for the individual patient by trial participa-
tion, but from the answers we cannot know if they under-
stood the concept of clinical trials. Therefore qualitative
interviews of relatives would be of interest to assess if
understanding for example the concept of randomisation
would change their answers.
The majority of the relatives in our study expressed a
wish for the treating clinician or ICU consultant to give
consent to trial participation. It may be speculated that
this is due to insecurity and a wish to share the responsi-
bility with someone who knows the current medical sta-
tus of the patient. In the Swiss study of ICU survivors and
their relatives the majority wanted consent from two per-
sons [7], but only 30% of the relatives wanted the inten-
sivist to be one of these two. The reason for this
discrepancy may be the timing of the two studies. In our
study we included relatives within 48 hours of ICU
admission whereas in the Swiss study the questionnaire
was mailed to the relatives 3 years after ICU discharge.
The use of deferred consent in emergency situations
may be supported by the data from the present study and
those from recent studies of ICU patients and relatives
[7,11]. An ethical analysis of emergency critical care
research also supported the use of delayed consent [12].
Table 1: General attitudes to drug trials among 42 relatives of unconscious adult ICU patients
Choices (percentages)
Question It is a natural part of any 
admission
Sceptical, but realize the 
necessity
Should not be 
allowed
Do not know
What do you think of drug trials in general? 15 (36) 25 (60) 1 (2) 1 (2)
What do you think of drug trials in 
unconscious patients?
9 (21) 27 (64) 3 (7) 3 (7)
Table 2: Attitudes to participation in drug trials among 42 relatives of unconscious adult ICU patients
Choices (percentages)
Question Would accept Would most likely 
accept





How is your attitude to your 
own potential participation in a 
drug trial?
11 (26) 23 (55) 5 (12) 2 (5) 1 (2) -
How is your attitude if your 
relative, who is in intensive care, 
was to participate in a drug trial?
8 (19) 22 (52) 8 (19) 2 (5) 1 (2) 1 (2)
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Question Grading (percentages)
What would matter if your relative was to 
participate in a drug trial here in the intensive 
care unit?
Very important Important Minor importance Not important Do not know
'That current legislation was followed' 29 5 5 1 2
'That my relative was to gain directly from the trial' 22 13 6 0 1
'That future patients will gain from the trial' 23 15 1 0 3
'That new knowledge is accomplished to develop 
new therapies'
26 11 2 0 3
'That there is no risk by participation' 24 10 3 0 4
'That there is no discomfort by participation' 22 10 6 1 3
What motives do you think doctors have when 
they perform drug trials?
'Wish to find new treatments' 39 1 0 0 2
'Wish to help patients' 38 3 0 0 1
'Wish to reduce overall cost of treatment' 0 10 15 12 5
'Wish to gain new knowledge' 33 7 1 0 1
'Wish to make carrier' 4 12 13 8 5
'Wish to earn money' 0 5 12 19 6
More than one answer could be marked.
On the other hand waiver of consent may not be sup-
ported, as it appeared to unacceptable to the relatives in
the present study (not directly assessed) and a previous
study [7]. Waiver of consent does increase inclusion rates
[13], but high rates could likely be obtained using proxy
consent by the treating clinician. Therefore, a consent
procedure may be proposed for emergency situations
where proxy consent is given by the treating clinician fol-
lowed by deferred consent by the relative.
There are a number of strengths to this study. We pro-
spectively included consecutive relatives within 48 hours
of admission of their relative to the ICU. It is possible that
attitudes of relatives change over time in the ICU, thus we
have limited this potential confounder. Also, the relatively
high response rate makes it likely that the overall results
are representative for the whole cohort of relatives at least
those of the including units, which covers city, suburban
and countryside areas in Denmark.
There are also some weaknesses to the study. It was
performed in a single Scandinavian country, so it is
unknown if the results can be transferred to other coun-
tries or regions. This reduces the generalisability, because
differences in culture and trust in the health care system
and authorities in general are likely to influence the atti-
tude to research. Due to limits in sample size, the influ-
ence of age and gender cannot be explored conclusively.
As mentioned above, the attitudes presented here are
those of the first 2 days after acute ICU admission. As we
have no data on attitudes later in the admission period,
the results are applicable only for those first days in the
ICU. Also we have asked specifically about drug trials, so
we do not know the attitude towards other types of stud-
iesFinally, we did not include relatives who had been
asked to consent for a patient trial. It may therefore be
argued that the questions were theoretical for the rela-
tives, therebyinfluencing their answers. On the other
hand if the participants had been through the consent
procedure for a trial prior to survey, the specific charac-
teristics of this trial may also have influenced their
answers. Taken together, a future survey should study a
large sample in more countries and regions including
both relatives that had and had not beenthrough a con-
sent procedure prior to survey.
Hopefully, we will acquire more knowledge and data on
ICU patients' and their relatives' attitudes towards trials,
so that politicians can base future legislation on sound
science. The present rigid consent procedures are likely
to be a barrier for future research and scientific develop-
ment in the critical care setting [14]. If we can match the
process of consent to the attitudes and expectations of
patients and relatives, more rational trial conduct is likely
to result to the benefit of all involved in ICU trialsand
society.
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In general, relatives to unconscious ICU patients
expressed positive attitudes to drug trials in the ICU and
the inclusion of their relative in drug trials. Consent by
next-of-kin and deferred consent was acceptable to the
majority of the relatives to unconscious ICU patients.
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